Alnylam Pharmaceuticals (ALNY) has come back into focus after the company outlined 2030 financial goals and reiterated AMVUTTRA’s central role, even as fresh headlines highlighted its AI partnership with Inceptive Nucleics.

Despite the recent AI collaboration and refreshed 2030 goals, Alnylam’s share price has been under pressure year to date, with a year to date share price return of down 25.6%. However, the 3 year total shareholder return of 50.7% and 5 year total shareholder return of 78.8% point to longer term holders still sitting on meaningful gains, suggesting recent sentiment has cooled rather than fully reversing the broader story.

If you are watching how AI is reshaping drug development, this could be a useful moment to see what else is on your radar through 39 healthcare AI stocks

With Alnylam’s stock down 25.6% year to date but still carrying an implied discount to analyst price targets and intrinsic value estimates, you have to ask: is there a mispricing here, or is the market already incorporating expectations for future growth?

Most Popular Narrative: 39.5% Undervalued

At a last close of $297.69 versus a narrative fair value of $491.92, the widely followed model paints a sizeable gap that hinges on sustained earnings and cash flow strength.

The analysts have a consensus price target of $426.26 for Alnylam Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $583.0, and the most bearish reporting a price target of just $236.0.

Want to see what underpins that gap between price and fair value? Revenue compounding, margin expansion, and a premium future earnings multiple all sit at the core of this narrative.

Result: Fair Value of $491.92 (UNDERVALUED)

However, this hinges on AMVUTTRA’s momentum and the wider TTR franchise holding up, with any pricing pressure or weaker than expected launch trends representing a clear risk.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle on Valuation: Earnings Multiple Tells a Tougher Story

The fair value narrative and DCF style thinking point to Alnylam as heavily undervalued, yet the current P/E of 73.9x is far above both the US Biotechs industry at 16.4x and the peer average at 26.2x, and more than double the fair ratio of 32.4x, raising the question of how much optimism is already in the price.

To see how the current pricing stacks up against earnings based metrics in more detail, including that higher P/E versus industry, peers and the fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment across the article is mixed. If you think the clock is ticking on this setup, review the upside case in the 4 key rewards

Looking for more investment ideas?

If this setup has you thinking harder about where to put your capital next, do not stop at one stock when there are plenty of other opportunities to review.

• Target dependable income streams by scanning companies described as 9 dividend fortresses and see which ones fit your approach to regular cash returns.
• Hunt for potential mispricings by reviewing 46 high quality undervalued stocks and compare how those stocks stack up against what you already own.
• Prioritise resilience by checking out 63 resilient stocks with low risk scores and see which stocks align with your comfort level on volatility and downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.